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Abstract Psoriatic arthritis (PsA) is characterized by focal
bone erosions mediated by osteoclasts at the bone–pannus
junction. The bulk of research over the past decade has
centered on mechanisms that underlie osteoclastogenesis
along with new insights into osteoimmunology; however,
recent advances that focus on steps that lead to new bone
formation are beginning to emerge. New revelations about
bone formation may have direct relevance to PsA given the
presence of enthesophytes, syndesmophytes, and bony an-
kylosis frequently observed in patients with this disorder. In
this review, we discuss current developments in the patho-
genesis of new bone formation, novel imaging approaches to
study bone remodeling and highlight innovative approaches to
study the effect of inflammation on bone. Lastly, we discuss
promising therapies that target joint inflammation and osteitis
with the potential to mediate pathologic bone formation.
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Introduction
The maintenance of bone homeostasis is dependent on a
balance between osteoclasts—cells that resorb bone—and
osteoblasts—cells that form bone [1]. The past decade of
research has yielded critical insights into mechanisms that
underlie joint damage, but the most recent studies have
unveiled an array of fascinating molecules that modulate
signaling pathways of bone formation. With respect to pso-
riatic arthritis (PsA), long-term consequences of joint in-
flammation are development of bone erosions alongside
new bone formation in the form of syndesmophytes, enthe-
sophytes, and ankylosis (peripheral bony fusion) [2, 3]. Data
from Schett and others have further validated differences in
the bone pathologies of PsA and rheumatoid arthritis (RA)
using new imaging modalities such as micro-CT and have
lent credence to the concept of divergent mechanisms of
bone repair in these two arthropathies [4]. New insights into
cytokine pathways that involve interleukin (IL)-17 and IL-
33 may further differentiate mechanisms of bone resorption
and repair in PsA and RA and likely will uncover additional
therapeutic targets.
Recognition of bone as an active organ that interacts
with its environment is a relatively new development [1,
5]. Indeed, the number of molecules with dual roles in
bone and immune function is ever-increasing and shows
the complexity of the field of osteoimmunology; it may
also explain clinical findings such as the notable fragility
of bone in patients with chronic autoimmune conditions.
Prior hypotheses have suggested use of medications such
as steroids to potentially explain increased bone demin-
eralization, but work in osteoimmunology points to spe-
cific inflammatory mediators that can target signaling
pathways and exert negative effects on bone homeostasis
[6–8].
Another central question focuses on pathways of bone
formation and includes the view that endochondral bone
formation, in which a cartilage template is replaced by bone
via the differentiation of chondrocytes into osteoblasts, may
be critical in arthritic diseases and is influenced by inflam-
matory signals that promote osteoblastogenesis [9].
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In this paper, we discuss the evolving field of osteoim-
munology and how inflammation in PsA and other inflam-
matory arthritides is leading to new insights into bone
remodeling, in particular with regard to new bone formation.
We also present recent information gained from novel
instruments that image joint and bone inflammation and
discuss how current therapies for the treatment of inflam-
matory arthritis may also affect bone homeostasis.
Mechanisms of Bone Formation
Chronic joint inflammation is associated with eventual de-
velopment of bone erosions; however, new bone formation
is also observed in patients with inflammatory arthritis, in
particular in PsA patients. The development of bony nod-
ules can be seen at sites different from erosions, suggesting
an uncoupling of the osteoblast–osteoclast homeostasis that
allows for regulated bone turnover and formation [10]. The
potential pathways involved in new bone formation include
the Wingless (Wnt), transforming growth factor (TGF)-β/
bone morphogenetic protein (BMP), and prostaglandin (PG)
E2 pathways [11].
Wnt Signaling
The Wnt/B-catenin signaling pathway promotes osteoblast
formation by stimulating Runx2, the key transcription factor
in activation of genes that mediate osteoblast development.
The critical details of osteoblastogenesis are currently under
investigation, even as new therapies are in development to
target molecules of this pathway. For example, Dickkopf-1
(DKK-1), as a natural antagonist of the Wnt pathway, plays
a crucial role in bone remodeling. The impact of anti–DKK-
1 antibody on bone formation was analyzed in tumor necro-
sis factor (TNF)-transgenic mice [12]. Microcomputed to-
mography (micro-CT) and histopathologic studies
demonstrated that bone erosions resolved in joints of mice
treated with anti–DKK-1 even in the presence of active joint
inflammation. Interestingly, osteophytes developed at the
inflamed joints of mice given anti–DKK-1 antibody, a find-
ing not observed in untreated mice. As this murine model
typically does not develop osteophytes, this provides pre-
liminary evidence that DKK-1 may act to inhibit local bone
formation. The investigators also examined DKK-1 in RA
patients, and increased serum levels were observed com-
pared with control patients or patients with ankylosing
spondylitis (AS); furthermore, higher levels correlated with
increased disease activity.
With regard to new bone formation, a study of AS
patients found a correlation between decreased serum levels
of DKK-1 and syndesmophyte development when com-
pared with healthy control patients [13], contradictory to
prior investigations showing increased DKK-1 serum levels
and syndesmophyte formation. The prior methods had mea-
sured total DKK-1 levels, whereas Heiland et al. [13] had
used an ELISA that measured functional DKK-1 levels as
determined by the amount of serum DKK-1 bound to its
receptor. The investigators also noted a significant corre-
lation between lower serum levels of DKK-1 and the
protein sclerostin, another natural inhibitor of Wnt sig-
naling and negative regulator of bone formation. These
findings point to the possible use of DKK-1 and sclero-
stin as biomarkers of patients at increased risk of devel-
opment of progressive ankylosis. Given that increased
levels of DKK-1 and sclerostin correlate with syndesmo-
phyte formation as outlined above, it is plausible that
PsA patients with evidence of new bone formation would
also demonstrate elevated levels of these Wnt pathway
inhibitors. In contrast, a study by Daoussis et al. [14]
that examined levels of DKK-1 in patients with AS, RA,
PsA, and controls found elevated DKK-1 levels in
patients with AS, but not those with PsA or RA. Clearly,
more information is required to elucidate the importance
of Wnt signaling and its inhibitors in the process of new
bone synthesis in PsA. Certainly the marked heterogene-
ity of bone phenotypes in PsA complicates interpretation
of data and requires a careful assessment of the degree
and type of bone pathology (axial, peripheral, erosive,
proliferative, or a combination of involvement) in indi-
vidual patients.
The TGF-β Superfamily
Another prominent area of study in bone formation has been
the TGF-β family, which includes the TGF-βmolecules and
BMPs [15]. In the canonical TGF-β/BMP pathway, trans-
ducer proteins called Smad form a complex through a series
of phosphorylation events that leads to translocation of the
Smad complex into the nucleus of mesenchymal stem cells
to activate bone-specific genes, including the key regulator
in bone formation, Runx2 [16]. The subsequent transloca-
tion and gene activation commits the stem cells to osteoblast
lineage. Several steps along this path have been studied as
potential therapeutic targets, including parathyroid hormone
(PTH) and its effects on Smad activation. Additionally,
TGF-β is believed to work directly on the PTH receptor to
mediate bone remodeling as related to bone formation [17].
A series of experiments by Redlich et al. [18] examined
local and systemic bone loss in the TNF transgenic mouse
and the effect of anti-TNF therapy combined with bone
formation therapy via the use of PTH. They showed osteo-
blast function is decreased, leading to decreased bone for-
mation, and anti-TNF therapy alone did not result in bone
repair. However, combination anti-TNF and PTH led to
resolution of bony erosions and new bone formation. When
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considering AS or PsA patients, it is possible that PTH
analogues in combination with anti-TNF therapy could im-
prove or repair bone homeostasis.
BMP
Recent data suggests that BMPs as a group may be more
influential in bone formation than TGF-β. In a study by the
Lories et al. [19] laboratory, inhibition of BMP signaling
blocked development of ankylosis in a murine model of
arthritis, with phenotypic findings similar to AS and PsA,
including enthesitis, ankylosis, and dactylitis [19]. In a
unique experiment, they inhibited BMP using gene transfer
to induce production of noggin, a natural inhibitor of BMP.
Through histochemical analysis of joints of mice with and
without BMP inhibition, mice transfected with plasmid
cDNA plus noggin had decreased ankylosing enthesitis
and inhibition of bone formation. Similar histochemistry
was seen in human entheses specimens of patients with
spondyloarthropathy. In PsA patients, in whom enthesitis
and new bone formation are common findings, signaling
molecules in the BMP pathway may be a reasonable target
for new agents designed to block accumulation of patholog-
ic bone.
Although the pathways in bone formation mentioned
above are often studied separately, in reality, there is a
complex interplay between them, only some of which has
been defined. For example, in a series of experiments using
a murine model in which the BMP receptor was knocked
out, investigators noted upregulation of Wnt signaling, pos-
sibly by targeting Wnt inhibitors DKK-1 and sclerostin [20].
The mice lived to adulthood and had increased bone mass
throughout. The findings suggest that studies examining
both the BMP and Wnt pathways may provide new insights
into synergistic and interactive components in the regulation
of bone growth.
Prostaglandin E2
PGE2 is a derivative of arachidonic acid that has been acted
on by cyclooxygenase (COX) and PGE synthase and is
involved in triggering inflammation and pain [21]. The
PGE2 pathway is also integrally involved in skeletal forma-
tion through effects on osteoblast differentiation [22]. Zhang
et al. [22] have shown that in COX1 and COX2 knockout
mice, bone healing is impaired due to defective osteoblasto-
genesis. This impairment is resolved with addition of PGE2
and BMPs, suggesting a link between the PGE2 and BMP
pathways. Of the subtypes of PGE2 receptors, EP2 and/or
EP4 are involved in bone formation and repair [23]. This
recent information suggests that NSAIDs may help relieve
inflammation and possibly inhibit new bone synthesis in
conditions such as AS or PsA. In fact, Wanders et al. [24]
demonstrated a greater effect of continuous versus intermit-
tent treatment with celecoxib on inhibition of syndesmo-
phytes in AS, and a recent study showed that NSAIDs plus a
TNF antagonist were more effective in the prevention of
accumulation of syndesmophytes over time than anti-TNF
monotherapy [25]. These studies provide preliminary data to
formally address the role of NSAIDs in the prevention of
bone fusion in the spondyloarthropathies.
TNF/RANKL
To understand the relationship of TNF and bone, one must
first appreciate the actions of the protein receptor activator
of nuclear factor-κB (RANK) [26]. The RANK transmem-
brane protein is expressed on both osteoclast precursor cells
and on fully functional osteoclasts. Upon ligand binding by
the RANK ligand (RANKL), the protein acts on adaptor
molecule TNF receptor–associated factor (TRAF)-6 to acti-
vate nuclear factor-κB (NF-κb), subsequently leading to
osteoclastogenesis. The transcription factor activated at the
terminus of this pathway is nuclear factor of activated T
cells, cytoplasmic 1 (NFATc1). This key regulator of osteo-
clastogenesis was first noted in T cells and later found to be
intimately associated with bone remodeling [27]. However,
it remains unclear how the activation of RANK alone trig-
gers intracellular calcium signaling.
Similar to T- and B-cell signaling and the necessity of a
secondary signal in order to activate immune pathways, it
has been established that activation of osteoclastogenesis
requires the presence of a second signal [27]. One possible
candidate co-stimulatory pathway involves the triggering
receptor expressed in myeloid cells-2 (TREM2)/DAP12/
OSCAR molecules. DAP12 is an adaptor molecule found
on the surface of cells of myeloid lineage, including osteo-
clasts, and contains a specialized region known as an ITAM
(immunoreceptor tyrosine-based activation motif) necessary
for signaling. It is complexed with TREM2 and OSCAR in
osteoclasts, leading to a cascade of signaling events that
terminate with NFATc1 stimulation by calcium/calcineurin
[27]. The ligand of OSCAR was recently suggested to be a
neoepitope of fibrillar collagen [28], and the TREM2 ligand
remains to be discovered; the source of the ligands for both
receptors remains unclear, although work by Koga et al. [29]
has suggested that the cells responsible may be osteoblasts.
If this is the case, it could provide an explanation for the
impairment in both osteoblast and osteoclast function seen
in PsA patients and possibly demonstrate why PsA appears
to have a different pathogenesis than RA.
Bruton’s Tyrosine Kinase Inhibition
In elucidating this secondary signal of osteoclastogenesis,
one group of molecules being investigated is the Bruton’s
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tyrosine kinase (Btk) family found on cells with a hemato-
poietic origin, including B cells, monocytes, and mast cells.
Btk is involved in cell proliferation, antibody formation, and
release of inflammatory cytokines such as TNF-α, specifi-
cally acting in the TREM/DAP12 pathway [30, 31]. As
similar processes are dysregulated in autoimmune condi-
tions, Btk may play a role in diseases such as inflammatory
arthritis. Evidence of this has been seen in murine models of
collagen-induced arthritis (CIA), in which arthritis symp-
toms are ameliorated by Btk small molecule inhibitors.
However, given that multiple hematopoietic cell types are
involved in CIA, it remains unclear how Btk mediates
inflammatory erosive arthritis.
Btk functions in osteoclast differentiation by affecting the
stimulation of NFATc1, the known key regulator of osteo-
clastogenesis [32]. This was found by studying mice with a
Btk mutation and noting an impairment of cell–cell fusion
(to form multinucleated giant cells) and decreased NFATc1
expression in osteoclast precursors. Additionally, human
Btk-deficient osteoclasts from X-linked agammaglobulin-
emia (XLA) patients are defective at bone resorption activ-
ity in vitro, potentially owing to dysregulation of actin
cytoskeletal function [33]. These inherent osteoclast defects
are corrected by increased inflammatory cytokine levels,
which restore osteoclast activity to normalize bone density
in these patients. Thus, current evidence points to Btk as a
valid candidate co-stimulatory signal in osteoclastogenesis.
Studying the Btk pathway is important from the perspective
of inflammatory arthritides (e.g., PsA) because inhibition of
this molecule may decrease both joint inflammation and
osteoclastogenesis.
Semaphorins
In addition to Btk, another family of molecules just
emerging in osteoimmunology is the semaphorins. Sem-
aphorin 4D (Sema4D), originally noted to be an axon
guidance molecule [34, 35], has recently been found to
have activity in bone remodeling. In a paper by
Negishi-Koga et al. [36], Sema4D was shown to be
secreted by osteoclasts in order to inhibit osteoblast
formation via binding to a cell-surface receptor called
plexin-B1, leading to decreased bone formation and
overall bone loss. Inhibition of Sema4D in a murine
model of osteoporosis led to bone formation by stimu-
lation of osteoblasts and subsequently reversed bone
demineralization. It is not known whether inhibition of
Sema4D would ameliorate bone loss seen in inflamma-
tory arthritis. As both osteoblast and osteoclast functions
are dysregulated in PsA, it is possible that semaphorins
may provide the critical clue to understanding the in-
congruous finding of new bone formation alongside
bone erosions.
Imaging and Bone Pathology
Rheumatology has long used imaging as a means to aid in
diagnosis of disease and for measuring outcome after initia-
tion of therapy in PsA; recent work has brought to light other
modalities useful for diagnosis at the earliest stages of disease.
MRI
The use of MRI to evaluate and assess inflammatory arthrit-
ic conditions has become routine in rheumatology to mini-
mize exposure to radiation-based modalities. In the
inflammatory arthritides, patients with RA have been eval-
uated and there has been a noted increase in bone edema in
this group; however, few studies have looked at MRI in PsA
until recently. A study by McQueen et al. [37] looked at the
effect of the bisphosphonate zoledronic acid in a small
group of PsA patients. Of the six patients on drug versus
the six on placebo, they noted that there was no difference in
bone erosion scores between the two groups after 1 year.
However, there was decreased bone edema, suggesting de-
creased osteitis as well as decreased disease activity in the
treated group. This suggests that bisphosphonates may be
useful in PsA patients with regard to ameliorating bone and
joint inflammation; however, the lack of effect on resolving
erosions may mean that osteoclastogenesis is occurring via a
different pathway than in patients with osteoporosis.
Ultrasound
Interest in the use of ultrasound (US) to assess inflammation
has been reignited given the ability of clinicians to perform
the examination in the office as well as the cost–benefit
analysis compared with other modalities. Furthermore, in-
creasingly sophisticated machines have greatly improved
the image quality, and new techniques such as Doppler
and contrast have improved the value of the information
obtained from US. One recent study looked at PsA patients
and compared MRI with contrast enhanced US (CEUS) in
diagnosis of early PsA [38], concluding that CEUS is as
effective as contrast MRI in detecting early PsA and more
effective than noncontrast MRI for early diagnosis. Al-
though there were a small number of patients studied (n0
17), the 100 % concordance rate between MRI and CEUS in
diagnosing PsA is impressive and points to the efficacy of
CEUS in detecting inflammation.
There have been US studies focusing on several aspects
of PsA, including bony erosions, axial disease, and swelling
[39]. However, a key use of US in PsA is to evaluate
enthesitis. Inflammation at the sites of tendon insertion is a
key finding in PsA patients, and it can be difficult to assess
this by clinical examination or conventional radiography,
especially in clinically asymptomatic patients. A unique
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study by Gutierrez et al. [40] looked entheses sites by power
Doppler (PD) US in patients with psoriasis alone and noted
32 % to have evidence of entheseal inflammation, compared
with 8 % in a healthy population. These findings suggest
that PD US of entheses in PsA patients may be helpful in
detecting subclinical disease, which could alter therapeutic
management. However, larger studies will be needed to
validate these findings and should include a population with
early PsA to determine if subclinical etheseal involvement
can be detected. Furthermore, similar to MRI, there are
limited studies focusing on using US to detect new bone
formation in PsA patients.
Micro-CT
Micro-CT is an imaging modality that can reliably provide
high-quality images of bone erosions [41], and a study by
Finzel et al. [4] using this instrument noted a novel differ-
ence in patients with RA versus PsA. The investigators
looked at 30 patients with PsA compared with 58 patients
with RA and evaluated the second through fourth metacar-
phophalangeal joints of the dominantly affected hand. The
number of erosions between the two groups was similar, but
they noted three distinct types of erosions. Intriguingly, PsA
patients had more bottle neck–shaped erosions, with a small
cortical break and large erosion beneath and tubule-shaped
lesions suggestive of cortical tunnels, although the sizes of
the erosions were smaller compared with the RA group. RA
patients had U-shaped erosions with wide cortical breaks
but smaller erosions beneath and were more likely to be
present on the radial side of the joint. The investigators
suggested that this difference in location, type, and size of
erosion between PsA and RA patients could indicate that
there is increased bone formation activity in PsA patients at
the cortical surface, leading to smaller erosions and indicat-
ing a different repair potential in PsA patients compared
with RA. This was further corroborated by the increased
number of osteophytes seen in the PsA population.
Update on Treatment
Because of the increased study of signaling pathways, targeted
therapy with biologics and small molecules has greatly ex-
panded the armamentarium of potential agents against inflam-
mation. In the seronegative inflammatory arthropathies, such
as PsA and AS, anti-TNF agents have resulted in dramatic
changes in the therapeutic approach [42]; however, with re-
gard to effects on bone, studies are still in the early stages to
define the precise role of anti-TNF agents and other biologic
agents and small molecules in the amelioration of new bone
formation. Table 1 describes some of these agents and the
possible effects on bone homeostasis.
Monoclonal Antibodies
The TNF antagonists have been the most extensively stud-
ied with regard to effects on bone [43, 44]. In PsA, anti-TNF
agents decrease synovitis, enthesitis, and dactylitis and re-
tard bony progression [45–47]; however, they do not slow
down new bone formation in the axial skeleton, although the
effect of these agents on peripheral new bone formation is
not known. Overall, these agents likely have an effect on
inhibition of osteoclastogenesis via TNF blockade [43]. The
ability of these agents to promote healing of bone in PsA
has not been evaluated. Another molecule with potent
effects on bone is anti-RANKL antibody (denosumab),
currently approved for the treatment of osteoporosis
[48–50]. This agent blocks bone degradation but can also
promote new bone formation, as shown by the increased
bone density in osteoporotic patients treated with this
agent and in preclinical models. Given that the RANKL
pathway in osteoclastogenesis is likely involved in PsA
and bone erosion development, this is a potential future
therapeutic in this group when combined with an anti-
inflammatory agent.
Small Molecule Inhibitors
Apremilast is a type 4 phosphodiesterase (PDE4) inhibitor
that has been recently studied in psoriasis and PsA as well as
other inflammatory arthritides [51–53]. It is thought to in-
directly block TNF effects due to its inhibition via the cyclic
adenosine monophosphate pathway. Because of this, it is
believed that any effect on bone is via osteoclastogenesis
and TNF blockade. Inhibitors of the JAK family of non-
receptor tyrosine kinases, which are stimulated by various
cytokines, have been shown to ameliorate inflammation in
murine models of inflammation and in RA [54]; however,
the mechanism of inhibition is unclear. No studies to date
have evaluated bone homeostasis in patients treated with
apremilast or JAK inhibitors, but given the prominent role
of inflammatory cytokines on osteoclastogenesis, it is cer-
tainly possible that an indirect effect of JAK and PDE4
inhibition is a lower state of bone resorption. In support of
the potential bone-protective effects of JAK inhibitors, van
der Heijde et al. [55] presented data showing that the oral
JAK inhibitor tofacitinib was associated with decreased
radiographic progression in RA patients after 1 year of
therapy.
NSAIDs
Use of NSAIDs in seronegative inflammatory arthritis is
still an initial treatment modality, especially given numerous
studies showing rapid clinical relief of pain and stiffness.
However, despite their widespread use, few studies have
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Table 1 Current and potential agents in PsA and effects on bone remodeling
Therapeutic Target(s) Molecular structure FDA indication Effects on bone
Anti-TNFa TNF, TNF receptor Antibody or receptor
antagonist
RA, PsA, AS, JIA, plaque
psoriasis, Crohn’s disease
Inhibits inflammation and osteoclastogenesis,
may stimulate osteoblast differentiation
[43, 44]





Antibody Plaque psoriasis Inhibits inflammation and osteoclastogenesis
[56]
Anti–IL-17 IL-17, Th17 cells Antibody, small
molecule against
Th17 cells
Phase 1/2 trials Inhibits inflammation and osteoclastogenesis
(via effects on osteoblasts and possibly
other cells) [61]
Anti–IL-1d IL-1, IL receptor Antibody, fusion protein RA, sJIA, autoinflammatory
conditions









Small molecule Phase 3 trials Inhibits osteoclastogenesis (via effects on
osteoblasts and possibly other cells) [64]






AS ankylosing spondylitis; FDA US Food and Drug Administration; IL interleukin; JIA juvenile idiopathic arthritis; PsA psoriatic arthritis; RA
rheumatoid arthritis; RANKL receptor activator of nuclear factor-κB ligand; sJIA systemic JIA; Th17 T-helper type 17 cell; TNF tumor necrosis
factor
Fig. 1 Dual aspects of altered bone remodeling in psoriatic arthritis. In
the presence of certain differentiation signals, mesenchymal stem cells
are induced to become osteoblasts, bone-forming cells. Osteoblasts are
then stimulated by via pathways including bone morphogenetic pro-
teins (BMP), prostaglandin (PG)E2, and Wingless (Wnt) signaling.
This leads to activation of the master transcription factor RUNX-2
and subsequent new bone formation. The natural antagonist of BMP
is Noggin and of the Wnt pathway is Dickkopf-1 (DKK1) and Sclero-
stin; antibodies to these molecules are currently in development to
promote bone formation. In bone resorption, osteoclasts derived from
precursors receive signaling from inflammatory molecules such as
tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6. This acti-
vates the master regulator RANK ligand (RANKL) and subsequent
bone erosion. A natural inhibitor of osteoclast formation is osteopro-
tegerin (OPG). Several therapeutic agents (dark red) are used to block
steps in these pathways. Additionally, new molecules and pathways
such as Bruton’s tyrosine kinase (Btk), Plexin-B1/semaphorin 4D
(Sema4D), and transforming growth factor (TGF)-beta1 are being
studied, as their specific roles in bone remodeling have yet to be
clarified. FGF, fibroblast growth factor
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examined the effect of NSAIDs on bone. Studies looking
at NSAIDs in PsA patients are not available, although it
would be interesting to see if results would be similar to
AS studies suggesting a decrease in radiographic pro-
gression [24]. Moving forward, the standard of therapy
for axial SpA likely will shift to combination NSAID
and TNF inhibition; this therapy may likewise have
potential for axial PsA. Similarly to NSAID therapy,
disease-modifying antirheumatic drugs are still used as
a mainstay in treatment of PsA, but studies looking at
effect on bone are lacking.
Cytokine Research
The inhibition of proinflammatory cytokines (IL-1, TNF,
IL-6) has led to many new therapeutic agents that have
proven effective and relatively safe. More recently, investi-
gators have studied the IL-17 and IL-23 pathways [56]. A
phase 2b, double-blind, randomized, placebo-controlled,
crossover study of a monoclonal antibody against the shared
p40 subunit of IL-12 and IL-23 in PsA patients met the
primary end point of achieving an ACR20 in the treated
patients versus control patients [57]. The group also looked
at enthesopathy and dactylitis and noted improvement in
those findings in the treated group. Based on these data,
phase 3 studies were initiated and have recently been com-
pleted, but the results are pending. The studies looking at
these cytokines did not directly evaluate osteoimmunology,
but a study by Sato et al. [58] looking at IL-17 suggests that
promotion of osteoclastogenesis may occur indirectly via
osteoblasts. The study focused on the subgroup of T cells
known as T-helper type 17 (Th17) cells because they secrete
IL-17. Based on their experiments, the investigators suggest
that IL-17 does not directly affect osteoclasts but rather
stimulates osteoblasts to produce RANKL, leading to in-
creased RANK stimulation and subsequent osteoclastogen-
esis. Added to the story is that IL-17 is believed to be
downstream of IL-23; therefore, molecules targeting IL-23
likely would decrease IL-17 expression. In PsA, because it
is believed that there is an uncoupling of osteoblast–osteo-
clast homeostasis, it is possible that the inhibition of IL-17
may not have as profound an effect on osteoclastogenesis as
would be expected.
Studies of anti-inflammatory cytokines such as IL-33
[59, 60] suggest this cytokine can inhibit bone resorption
via amelioration of the effect of TNF on osteoclastogenesis.
Unlike the IL-23/IL-17 pathway, IL-33 therapy may be
effective in PsA and bone remodeling because of abrogation
of the effects of TNF-α on the RANKL pathway. Further
studies of anti-inflammatory cytokines will be necessary to
elucidate their effects on bone homeostasis and likely will
yield more therapeutic targets.
Conclusions
The effect of joint inflammation on bone is of particular
interest in PsA, and novel insights into osteoblast function
have led to further understanding of bone biology (Fig. 1). It
is clear that the signaling pathways such as RANK, Wnt,
and BMPs are much more interconnected than previously
thought. Similarly, continued research into osteoclastogene-
sis has helped elucidate pathways involved in bone resorp-
tion, leading to the development of new therapeutics,
including anti-RANKL agents and anticytokine therapeu-
tics. However, further work needs to be done in order to
understand the unique observation in psoriatic patients of
simultaneous bone formation and resorption, and suggests
that the osteoclast–osteoblast interplay can become
uncoupled in the inflammatory microenvironment of the
psoriatic joint and enthesis. The use of innovative imaging
techniques such as micro-CT and the improved quality of
US may help determine how effective the newest biologics
and small molecules are in controlling and inhibiting in-
flammation and subsequent bone and joint damage. More-
over, these instruments may provide important insights into
disease pathogenesis. As new insights into osteoimmunol-
ogy are acquired and applied to what is known about joint
disease, we will see the study of osteoblast and osteoclast
homeostasis become a pivotal area of focus in PsA.
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